Fortrea Holdings FTRE
NASDAQ FTRE
$18.16 -0.46 (-2.47%)
As of: Sep 4, 2026 · 1:30 PM EDT

Fortrea Holdings (FTRE) Cost of Revenue (2022 - 2026)

Fortrea Holdings' (FTRE) quarterly Cost of Revenue came in at $539.0 million in Q2 2026, down 6.55% YoY from $576.8 million in Q2 2025, and up 5.09% on a QoQ basis from $512.9 million in Q1 2026.

Analysis

Fortrea Holdings (FTRE) Cost of Revenue (2022 - 2026) Analysis & Trends

Fortrea Holdings (FTRE) has 5 years of Cost of Revenue data on file, last reported at $539.0 million in Q2 2026.

  • Quarterly Cost of Revenue fell 6.55% year-over-year to $539.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.2 billion (down 1.57% YoY) and the FY2025 annual result came in at $2.2 billion, up 2.65% from the prior year.
  • Cost of Revenue climbed to $539.0 million in Q2 2026, from $512.9 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $614.3 million in Q2 2022 to a low of $265.0 million in Q4 2022.
  • A 5-year average of $538.8 million and a median of $554.2 million in 2024 frame the typical range for Cost of Revenue.
  • Annual changes were most pronounced in 2023 — Cost of Revenue jumped 118.08% — and 2024, when it dropped 7.63%.
  • Tracing FTRE's Cost of Revenue over 5 years: stood at $265.0 million in 2022, then jumped by 118.08% to $577.9 million in 2023, then declined by 3.77% to $556.1 million in 2024, then fell by 4.8% to $529.4 million in 2025, then increased by 1.81% to $539.0 million in 2026.
  • The last three Cost of Revenue figures came in at $539.0 million (Q2 2026), $512.9 million (Q1 2026), and $529.4 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Vertex Pharmaceuticals 139.26 Bn 131.41 Bn 2.84 Bn 489.20 Mn
2 Regeneron Pharmaceuticals 85.64 Bn 77.64 Bn 3.93 Bn 360.70 Mn
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn 145.00 Mn
4 Moderna 57.83 Bn 52.69 Bn 52.00 Mn 93.00 Mn
5 Revolution Medicines 44.08 Bn 44.08 Bn - -
6 BeOne Medicines 39.94 Bn 34.84 Bn 1.53 Bn 174.53 Mn
7 Alnylam Pharmaceuticals 35.19 Bn 31.88 Bn 992.69 Mn 298.26 Mn
8 Royalty Pharma 28.42 Bn 27.58 Bn - -
9 Insmed 27.35 Bn 26.19 Bn 358.27 Mn 67.21 Mn
10 Fortrea Holdings 1.72 Bn 1.55 Bn 139.20 Mn 539.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 539.00 Mn
Mar 31, 2026 512.90 Mn
Dec 31, 2025 529.40 Mn
Sep 30, 2025 578.60 Mn
Jun 30, 2025 576.80 Mn
Mar 31, 2025 534.80 Mn
Dec 31, 2024 556.10 Mn
Sep 30, 2024 526.60 Mn
Jun 30, 2024 525.30 Mn
Mar 31, 2024 554.20 Mn
Dec 31, 2023 577.90 Mn
Sep 30, 2023 563.80 Mn
Jun 30, 2023 568.70 Mn
Mar 31, 2023 541.50 Mn
Dec 31, 2022 265.00 Mn
Sep 30, 2022 594.80 Mn
Jun 30, 2022 614.30 Mn